- Generic Name:
- Drug Type:
- Janus-associated kinase inhibitor
- How the Drug is Given:
Indications and Usage
Ruxolitinib is FDA approved for treatment of
- Intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults
- Polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea
- Steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.
Side effects needing medical attention
Bruising; dizziness; headache; urinary tract infection; weight gain; flatulence; herpes zoster; low platelet counts; low red blood cell counts; low white blood cell counts.
Tuberculosis has been reported in patients receiving ruxolitinib for myelofibrosis.
Progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death, has been reported with ruxolitinib treatment for myelofibrosis.